Gritstone bio, Inc.

GRTS

US39868T1051

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.7645 ^USD	-5.95%		+2.80%	-62.52%

Apr. 15	Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	CI
Apr. 02	Top Midday Decliners	MT

Gritstone Bio, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

August 05, 2021 at 04:08 pm EDT

Gritstone bio, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 2.843 million compared to USD 488,000 a year ago. Operating loss was USD 25.166 million compared to USD 26.057 million a year ago. Net loss was USD 25.118 million compared to USD 25.868 million a year ago. Basic loss per share from continuing operations was USD 0.33 compared to USD 0.69 a year ago. For the half year, total revenue was USD 42.536 million compared to USD 1.750 million a year ago. Operating loss was USD 17.270 million compared to USD 52.728 million a year ago. Net loss was USD 17.195 million compared to USD 52.074 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 1.41 a year ago.

Latest news about Gritstone bio, Inc.

Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	Apr. 15	CI
Top Midday Decliners	Apr. 02	MT
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants	Apr. 02	MT
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall	Apr. 01	MT
Gritstone Bio Starts Public Offering; Shares Drop After-Hours	Apr. 01	MT
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite	Apr. 01	CI
Earnings Flash (GRTS) GRITSTONE BIO Posts Q4 Revenue $16.3M	Mar. 05	MT
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial	Feb. 12	CI
Gritstone bio, Inc.(NasdaqGS:GRTS) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
B. Riley Adjusts Gritstone bio's Price Target to $6 From $8, Keeps Buy Rating	Dec. 07	MT
Transcript : Gritstone bio, Inc. Presents at First Annual Goldman Sachs Catalyst Clinic, Dec-05-2023 11:00 AM	Dec. 05
Earnings Flash (GRTS) GRITSTONE BIO Posts Q3 Revenue $1.6M	Nov. 08	MT
Gritstone bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna Vaccine Candidates Against Covid-19 (Part of the Company?s Coral Program) at IDWeek 2023	23-10-11	CI
Gritstone bio Offers Stock Options to Three New Employees	23-10-10	MT
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	23-09-28	MT
Piper Sandler Lifts Price Target on Gritstone bio to $7 From $6, Keeps Overweight Rating	23-09-28	MT
Gritstone Bio Gets Contract For Comparative COVID-19 Trial; Shares Jump After-Hours	23-09-27	MT
Gritstone Bio, Inc. Receives BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19	23-09-27	CI
Gritstone bio, Genevant Sciences Sign License Agreement for Use of LNP Technology	23-08-15	MT
Gritstone Bio and Genevant Sciences Announce Option and License Agreement	23-08-15	CI
Earnings Flash (GRTS) GRITSTONE BIO Reports Q2 Revenue $2M	23-08-09	MT
Gritstone bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Gritstone Joins Collaborative Cancer Research Initiative; Shares Rise 4% Pre-Bell	23-08-07	MT

Chart Gritstone bio, Inc.

Duration

Period

More charts

Company Profile

Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Neoantigen International Summit

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Gritstone bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7645 USD

Average target price

5.167 USD

Spread / Average Target

+575.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GRITSTONE BIO, INC.	-62.52%	86.49M
CSL LIMITED	-4.60%	87.31B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.86B
BIOGEN INC.	-21.76%	29.36B
UCB	+58.56%	24.49B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	17.31B
INCYTE CORPORATION	-18.49%	11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.17%	8.31B

Biopharmaceuticals